Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

My father's deaths.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2026
Same author

Rowing to the moon.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2025
Same author

DNR: "Do Not Resuscitate" or "Death Not Reversible"?

Journal of palliative medicine·2017
Same author

Time enough for tears?

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2016
Same author

The dance of death.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2013
Same author

Every physician a psychoanalyst? Implications of the Adverse Childhood Experiences study.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2011
Same journal

Elevated CK-MB With Normal Total Creatine Kinase Levels in Patients Undergoing Maintenance Hemodialysis-Reply.

Archives of internal medicine·2017
Same journal

Occult Carbon Monoxide Poisoning-Reply.

Archives of internal medicine·2017
Same journal

Acquired Immune Deficiency Syndrome-Reply.

Archives of internal medicine·2017
Same journal

Heparin Side Effects-Reply.

Archives of internal medicine·2017
Same journal

Humanizing primary care medicine begins with stress.

Archives of internal medicine·2017
Same journal

Legend omitted and number misrepresented.

Archives of internal medicine·2013
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay
05:52

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay

Published on: May 12, 2023

Life prolonging in name only?

Stephen Workman

    Archives of Internal Medicine
    |September 16, 2009
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Measuring Caenorhabditis elegans Life Span in 96 Well Microtiter Plates
    12:23

    Measuring Caenorhabditis elegans Life Span in 96 Well Microtiter Plates

    Published on: March 18, 2011

    Related Experiment Videos

    Last Updated: Jun 20, 2026

    Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay
    05:52

    Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay

    Published on: May 12, 2023

    Measuring Caenorhabditis elegans Life Span in 96 Well Microtiter Plates
    12:23

    Measuring Caenorhabditis elegans Life Span in 96 Well Microtiter Plates

    Published on: March 18, 2011